Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease

NCT05074498 is registered in ClinicalTrials.gov with TrueBinding, Inc. as lead sponsor.

NCT NCT05074498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease
Lead sponsor
TrueBinding, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 8, 2021
Completion date
October 13, 2022
Enrollment
154 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease